Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva confirms departure of chief executive officer

Teva confirms departure of chief executive officer

7th February 2017

Teva has announced that its chief executive officer (CEO) Erez Vigodman is stepping down from the role, as well as leaving the company's board of directors.

Following Mr Vigodman's departure, Dr Yitzhak Peterburg – who has served as chairman of the firm's board of directors since January 2015 – has been appointed interim president and CEO.

The interim leader has been a member of the board since 2012, having served a separate stint on the board from 2010 to 2011. Between these spells, he led Teva's innovative research and development efforts as group vice-president for global branded products.

Other previous roles include terms as president and CEO of Cellcom Israel from 2003 to 2005 and director general of Clalit Health Services, the leading healthcare provider in Israel, from 1997 to 2002.

Dr Peterburg said: "The company is focusing on executing its strategic priorities to transform Teva, with immediate focus on realising the cost synergies and strategic benefits of the Actavis Generics acquisition."

Meanwhile, Dr Sol Barer, who has been a member of the Teva board since January 2015, has been named as chairman following Dr Peterburg's move. A search has commenced for a new permanent CEO.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801832094-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.